Stocks · News reference

Bruker shares are trading lower after the company reported mixed Q2 financial results and cut its FY26 sales guidance below estimates.

Aug 4, 2026, 11:50 AMBenzinga Newsdesk

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 4, 2026, 11:50 AM
Checked: Aug 4, 2026, 11:50 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 11, 2026, 11:05 AMBenzinga Newsdesk
Bruker Announces Expanded Strategic Collaboration With And Minority Investment In Self-Driving Labs Firm Atinary Technologies; Terms Not Disclosed
Read original at benzinga
BRKR
BenzingaAug 10, 2026, 2:54 PMBenzinga Newsdesk
Bruker shares are trading higher after the company announced a majority investment in MIMETAS to expand its post‑genomic solutions and advance drug discovery through microphysiological systems.
Read original at benzinga
BRKR
BenzingaAug 10, 2026, 11:12 AMBenzinga Newsdesk
Bruker Announces Majority Investment In Organ-On-A-Chip Developer MIMETAS, Expanding Into Microphysiological Systems For Drug Discovery; Terms Not Disclosed
Read original at benzinga
BRKR
BenzingaAug 5, 2026, 6:51 PMBenzinga Newsdesk
Citigroup Maintains Neutral on Bruker, Lowers Price Target to $53
Citigroup analyst Brendan Digan maintains Bruker (NASDAQ:BRKR) with a Neutral and lowers the price target from $60 to $53.
Read original at benzinga
BRKR